Administration on Intellectual and Developmental Disabilities, President's Committee for People With Intellectual Disabilities, 63891-63892 [2018-26857]
Download as PDF
63891
Federal Register / Vol. 83, No. 238 / Wednesday, December 12, 2018 / Notices
application form and rank applications
by reported hypertension control rate.
In the second phase of assessment,
applicants with the highest preliminary
scores are asked to participate in a twohour data verification and validation
process. The applicant reviews the
application form with a reviewer,
describes how information was obtained
from the providers’, practices’, or
healthcare systems’ electronic records,
chart reviews, or other sources, and
reviews the methodology used to
calculate the reported hypertension
control rate. Data verification and
validation is conducted to ensure that
all applicants meet eligibility criteria
and assure accuracy of their reported
hypertension control rate according to a
standardized method. Applicants must
have achieved a hypertension control
rate of at least 80% among their adult
patients aged 18–85 years with
hypertension.
Finalists who pass the data
verification and validation process and
background check will be reviewed by
a CDC panel of judges to determine the
Champion status. Several Champions
will be asked to participate in a onehour, semi-structured interview and
provide detailed information about the
patient population served, the
geographic region served, and the
strategies employed by the practice or
health system to achieve exemplary
rates of hypertension control, including
barriers and facilitators for those
strategies. Based on the information
collected for Challenges in 2013 through
2017, CDC recognized a total of 83
public and private health care practices
and systems as Million Hearts®
Hypertension Control Champions. The
Champions are announced roughly
annually, approximately six months
after the Challenge application period
ends. The current OMB approval for
information collection expires
December 31, 2019.
CDC plans to continue the Million
Hearts® Hypertension Control Challenge
through 2022 with revisions. The 2020
Challenge is planned to launch in
February 2020, coinciding with
American Heart Month. The application
period will be open for approximately
45–60 days, with recognition of the
2020 Champions in the fall of 2020. A
similar calendar year schedule is
planned for 2021 and 2022. Revision for
2020, 2021, and 2022 includes a
reduction in the estimated number of
respondents. During the period of this
Renewal request, on an annual basis,
CDC estimates that information will be
collected from up to 200 applicants
using the application form, at most 40
data verifications, and at most 35 semistructured interviews. There is an
overall reduction in estimated
annualized burden hours.
The overall goal of the Million
Hearts® initiative is to prevent one
million heart attacks and strokes, and
controlling hypertension is one focus of
the initiative. CDC will use the
information collected through the
Million Hearts® Hypertension Control
Challenge to increase widespread
attention to hypertension at the clinical
practice level, improve understanding of
successful and sustainable
implementation strategies at the practice
or health system level, bring visibility to
organizations that invest in
hypertension control, and motivate
individual practices to strengthen their
hypertension control efforts.
Information collected through the
Million Hearts® Hypertension Control
Challenge will link success in clinical
outcomes of hypertension control with
information about strategies that can be
used to achieve similar favorable
outcomes so that the strategies can be
replicated by other providers and health
care systems.
OMB approval for a revision is
requested for three years. CDC estimates
that up to 200 applicants will submit an
application covered by this information
collection each year. It is estimated that
information collection activities will
total 215 burden hours per year. This
represents a decrease in the estimated
annualized burden hours from 370
hours to 215 hours. There is no cost to
respondents other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)
Total burden
(in hours)
Form name
Physicians,
Practices,
and
healthcare systems.
Finalists .............................................
Champions ........................................
Million Hearts® Hypertension Control Champion Application form.
Data Verification Form .....................
Semi-structured interview guide .......
200
1
30/60
100
40
35
1
1
2
1
80
35
Total ...........................................
...........................................................
........................
........................
........................
215
Jeffrey M. Zirger,
Acting Lead, Information Collection Review
Office, Office of Scientific Integrity, Office
of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2018–26876 Filed 12–11–18; 8:45 am]
BILLING CODE 4163–18–P
amozie on DSK3GDR082PROD with NOTICES1
Number of
responses per
respondent
Number of
respondents
Type of respondents
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Administration on Intellectual and
Developmental Disabilities, President’s
Committee for People With Intellectual
Disabilities
Administration for Community
Living, HHS.
ACTION: Notice of rescheduled meeting
due to the closure of federal offices on
December 5, 2018.
AGENCY:
The President’s Committee
for People with Intellectual Disabilities
SUMMARY:
VerDate Sep<11>2014
18:39 Dec 11, 2018
Jkt 247001
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
(PCPID) will host a webinar/conference
call for its members to discuss the
potential topics of the Committee’s 2019
Report to the President. All the PCPID
meetings, in any format, are open to the
public. This virtual meeting will be
conducted in a discussion format.
Webinar/Conference Call:
Wednesday, December 12, 2018 from
9:00 a.m. to 10:00 a.m. (EST).
DATES:
For
further information and
accommodations needs, please contact
Ms. Allison Cruz, Director, Office of
Innovation, 330 C Street SW, Switzer
Building, Room 1114, Washington, DC
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\12DEN1.SGM
12DEN1
63892
Federal Register / Vol. 83, No. 238 / Wednesday, December 12, 2018 / Notices
20201. Telephone: 202–795–7334. Fax:
202–795–7334. Email: allison.cruz@
acl.hhs.gov.
The
purpose of this virtual meeting is to
discuss the Committee’s preparation of
the 2019 Report to the President,
including its content and format, and
related data collection and analysis
required to complete the writing of the
Report. This meeting was originally
scheduled for December 5 from 9:00–
10:00 a.m. (EST). This meeting is
rescheduled to December 12 from 9:00–
10:00 a.m. (EST) due to the closure of
Federal offices on December 5 and to
allow for the call to occur before the end
of year.
Agenda: The Committee will discuss
the preparation of the PCPID 2019
Report to the President, including its
content and format, and related data
collection and analysis required to
complete the writing of the Report.
Webinar/Conference Call: The
webinar/conference call is scheduled for
Wednesday, December 12, 2018, 9:00
a.m. to 10:00 a.m. (EST) and may end
early if discussions are finished.
Instructions to Participate in the
Webinar/Conference Call on
Wednesday, December 12, 2018: Please
dial: (888) 949–2790; Pass Code:
1989852.
Background Information on the
Committee: The PCPID acts in an
advisory capacity to the President and
the Secretary of Health and Human
Services on a broad range of topics
relating to programs, services and
support for individuals with intellectual
disabilities. The PCPID executive order
stipulates that the Committee shall: (1)
Provide such advice concerning
intellectual disabilities as the President
or the Secretary of Health and Human
Services may request; and (2) provide
advice to the President concerning the
following for people with intellectual
disabilities: (A) Expanding employment
opportunities; (B) connecting people to
services; (C) supporting families and
caregivers; (D) strengthening the
networks; and (E) protecting rights and
preventing abuse.
amozie on DSK3GDR082PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
Dated: December 6, 2018.
Julie Hocker,
Commissioner, Administration on Disabilities
(AoD).
[FR Doc. 2018–26857 Filed 12–11–18; 8:45 am]
BILLING CODE 4154–01–P
VerDate Sep<11>2014
18:39 Dec 11, 2018
Jkt 247001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–D–4267]
Biomarker Qualification: Evidentiary
Framework; Draft Guidance for
Industry and Food and Drug
Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry and FDA staff
entitled ‘‘Biomarker Qualification:
Evidentiary Framework.’’ This draft
guidance provides recommendations on
general considerations to address when
developing a biomarker for qualification
under the 21st Century Cures Act (Cures
Act), enacted on December 13, 2016,
that added a new section to the Federal
Food, Drug, and Cosmetic Act (FD&C
Act). Qualification of a biomarker is a
determination that within the stated
context of use, the biomarker can be
relied on to have a specific
interpretation and application in drug
development and regulatory review.
DATES: Submit either electronic or
written comments on the draft guidance
by February 11, 2019 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–D–4267 for ‘‘Biomarker
Qualification: Evidentiary Framework;
Draft Guidance for Industry and FDA
Staff.’’ Received comments will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
E:\FR\FM\12DEN1.SGM
12DEN1
Agencies
[Federal Register Volume 83, Number 238 (Wednesday, December 12, 2018)]
[Notices]
[Pages 63891-63892]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-26857]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Administration on Intellectual and Developmental Disabilities,
President's Committee for People With Intellectual Disabilities
AGENCY: Administration for Community Living, HHS.
ACTION: Notice of rescheduled meeting due to the closure of federal
offices on December 5, 2018.
-----------------------------------------------------------------------
SUMMARY: The President's Committee for People with Intellectual
Disabilities (PCPID) will host a webinar/conference call for its
members to discuss the potential topics of the Committee's 2019 Report
to the President. All the PCPID meetings, in any format, are open to
the public. This virtual meeting will be conducted in a discussion
format.
DATES: Webinar/Conference Call: Wednesday, December 12, 2018 from 9:00
a.m. to 10:00 a.m. (EST).
FOR FURTHER INFORMATION CONTACT: For further information and
accommodations needs, please contact Ms. Allison Cruz, Director, Office
of Innovation, 330 C Street SW, Switzer Building, Room 1114,
Washington, DC
[[Page 63892]]
20201. Telephone: 202-795-7334. Fax: 202-795-7334. Email:
[email protected].
SUPPLEMENTARY INFORMATION: The purpose of this virtual meeting is to
discuss the Committee's preparation of the 2019 Report to the
President, including its content and format, and related data
collection and analysis required to complete the writing of the Report.
This meeting was originally scheduled for December 5 from 9:00-10:00
a.m. (EST). This meeting is rescheduled to December 12 from 9:00-10:00
a.m. (EST) due to the closure of Federal offices on December 5 and to
allow for the call to occur before the end of year.
Agenda: The Committee will discuss the preparation of the PCPID
2019 Report to the President, including its content and format, and
related data collection and analysis required to complete the writing
of the Report.
Webinar/Conference Call: The webinar/conference call is scheduled
for Wednesday, December 12, 2018, 9:00 a.m. to 10:00 a.m. (EST) and may
end early if discussions are finished.
Instructions to Participate in the Webinar/Conference Call on
Wednesday, December 12, 2018: Please dial: (888) 949-2790; Pass Code:
1989852.
Background Information on the Committee: The PCPID acts in an
advisory capacity to the President and the Secretary of Health and
Human Services on a broad range of topics relating to programs,
services and support for individuals with intellectual disabilities.
The PCPID executive order stipulates that the Committee shall: (1)
Provide such advice concerning intellectual disabilities as the
President or the Secretary of Health and Human Services may request;
and (2) provide advice to the President concerning the following for
people with intellectual disabilities: (A) Expanding employment
opportunities; (B) connecting people to services; (C) supporting
families and caregivers; (D) strengthening the networks; and (E)
protecting rights and preventing abuse.
Dated: December 6, 2018.
Julie Hocker,
Commissioner, Administration on Disabilities (AoD).
[FR Doc. 2018-26857 Filed 12-11-18; 8:45 am]
BILLING CODE 4154-01-P